| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 4, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on December 16, 2008 to shareholders of record on...
-
Oct 29, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...
-
Oct 23, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal year 2009 on Thursday, November 6, 2008 at approximately 8:00 a.m....
-
Oct 6, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired Laboratorios Diba, S.A. for approximately $25 million in cash. Based in Guadalajara, Mexico, privately-held...
-
Oct 3, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the JMP Securities 2008 Healthcare Focus Conference on Monday, October 6, at...
-
Sep 18, 2008
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the Hatch-Waxman litigation relating to Miconazole Nitrate Vaginal Cream and Suppository between Johnson & Johnson and Perrigo...
-
Sep 16, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired JB Laboratories for approximately $44 million in cash. Based in Holland, Michigan, privately-held JB Laboratories is...
-
Sep 15, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Judy Brown, Perrigo's CFO will present at the Merrill Lynch Global Pharmaceutical Conference on Tuesday, September 16 at the Merrill...
-
Sep 8, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the generic version of UCB's Xyzal®...
-
Aug 18, 2008- Full year revenue increased $375 million, or 26 percent, to a record $1.8 billion, including $500 million for the fourth quarter
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fourth quarter and full year ended June 28, 2008. Perrigo's Chairman and CEO Joseph C. Papa commented, "For the third...
-
Aug 13, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on September 16, 2008 to shareholders of record on...
-
Aug 11, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it began shipping Famotidine Complete chewable tablets (famotidine 10 mg; calcium carbonate 800mg; magnesium hydroxide 165 mg) to...
-
Aug 5, 2008In the release, Perrigo Company to Present at the Bank of America Specialty Pharmaceuticals Conference, issued earlier today by Perrigo Company (Nasdaq: PRGO; TASE), over PR Newswire, we are advised by the Company that the first sentence of the first para
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Judy Brown, Perrigo's Chief Financial Officer, will present at the Bank of America Specialty Pharmaceuticals Conference on Thursday,...
-
Aug 5, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Bank of America Specialty Pharmaceuticals Conference on Thursday,...
-
Aug 5, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2008 on Monday, August 18, 2008 at approximately 8:00 a.m. (ET). The Company...
-
Jul 15, 2008Company focused on producing quality, affordable healthcare
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO), the world's largest manufacturer of over-the-counter healthcare products sold under the store-brand label, announced today its intent to invest $10.5...
-
Jul 11, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors has appointed Ellen R. Hoffing as a new director of the Company. Joseph C. Papa, Perrigo's Chairman,...
-
Jul 7, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference on...
-
Jun 19, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup...
-
Jun 9, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application (ANDA) for Fluocinonide Cream 0.1%, a generic version of VANOS® Cream 0.1%. The...
-
May 21, 2008Company to Acquire Minority Interest in New Entity
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has entered into a collaborative agreement with Cobrek Pharmaceuticals, a newly formed entity of Pentech Pharmaceuticals Inc., a...
-
May 20, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Citi Investment Research Global Health Care Conference on Wednesday,...
-
May 6, 2008- Third quarter revenue increased $141 million, or 39 percent, to $504 million on important new product launches
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its third quarter fiscal year 2008 and nine months ended March 29, 2008. Perrigo Company (in thousands, except per share...
-
May 1, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on June 20, 2008 to shareholders of record on May...
-
Apr 24, 2008
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter (OTC) Nicotine Polacrilex...